Where to buy Vorinostat

Vorinostat (Vorinostat) is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients with progressive, persistent, or relapsing disease during or after receiving two systemic therapies. Vorinostat is generally well tolerated and shows potential anticancer activity against a variety of hematological and solid tumors, particularly in combination therapy as well as as monotherapy.

As monotherapy, comprehensive data from the vorinostat clinical trial program indicate that vorinostat has an acceptable safety and tolerability profile, with the most common grade 3/4 AEs being fatigue (12%) and thrombocytopenia (11%). Although tolerability data from Phase I trials of the vorinostat combination are limited, individual trial data indicate that the combination is generally well tolerated, and this is confirmed by pooled safety data from the vorinostat clinical trial program. Despite concerns, available data suggest that vorinostat does not appear to have any unexpected toxicities when used in combination with other antineoplastic agents. These preliminary clinical results from Phase I and II trials support the rationale for combining vorinostat with other chemotherapeutic agents and/or radiation therapy as a means of increasing the therapeutic index of cancer treatment.

The original drug of vorinostat is not currently on the market in China, so it cannot be covered by national medical insurance. Domestic patients cannot yet purchase this drug. Overseas, there is an American version of the original drug, specifications100mg*120 pills per box, which may cost around 100,000 yuan (the price may fluctuate due to exchange rate effects). It is very expensive, and there is currently no generic version of vorinostat produced and launched. For more drug information and specific prices, please consult a medical consultant.